Adjuvant sorafenib for hepatocellular carcinoma after radiofrequency ablation versus radiofrequency ablation: analysis of its efficacy and safety
Treatment with RFA+Sor treatment did not result in a longer OS than treatment with only RFA, however, the adverse effects of adjuvant Sorafenib were acceptable.
Authors
- Rui Liu (ORCID: https://orcid.org/0000-0001-9886-949X)
- Junxiao Wang (ORCID: https://orcid.org/0000-0001-7462-2716)
- Hui Xie
- Wen Zhenyu
- Sang Zejie
- Ding Mingchao
- Yang Xiang
Institutions
- Chinese PLA General Hospital (CN)
- Aerospace Center Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.3389/fonc.2024.1383312
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Beijing Science and Technology Planning Project